Nissim Darvish - 18 Mar 2026 Form 3 Insider Report for Chemomab Therapeutics Ltd. (CMMB)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
3
Accepted by SEC
10 Apr 2026, 16:12:30 UTC
Prior SEC filing
05 Jul 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Nissim Darvish

Key filing fact

Nissim Darvish filed Form 3 for Chemomab Therapeutics Ltd. (CMMB) on 10 Apr 2026.

Key facts

  • This page summarizes Nissim Darvish's Form 3 filing for Chemomab Therapeutics Ltd. (CMMB).
  • 0 reported transactions and 7 derivative rows are listed below.
  • Accepted by SEC: 10 Apr 2026, 16:12.

Change

  • Previous filing in this sequence was filed on 05 Jul 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001793602 Primary reporting owner

Darvish Nissim

Relationship
Director
Address
C/O CHEMOMAB THERAPEUTICS LTD., 10 HABARZEL ST., BUILDING C, 10TH FLOOR, TEL AVIV, ISRAEL
Signature
/s/ Nissim Darvish
Signature date
10 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CMMB holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
300
Date
18 Mar 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CMMB holding Derivative

Stock option (right to buy American Depositary Shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
American Depositary Shares
Underlying amount
2,531
Exercise price
$3.20
Footnotes
F1
CMMB holding Derivative

Stock option (right to buy American Depositary Shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
American Depositary Shares
Underlying amount
2,971
Exercise price
$109.04
Footnotes
F2
CMMB holding Derivative

Stock option (right to buy American Depositary Shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
American Depositary Shares
Underlying amount
1,705
Exercise price
$14.12
Footnotes
F3
CMMB holding Derivative

Stock option (right to buy American Depositary Shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
American Depositary Shares
Underlying amount
1,714
Exercise price
$6.48
Footnotes
F4
CMMB holding Derivative

Stock option (right to buy American Depositary Shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
American Depositary Shares
Underlying amount
5,143
Exercise price
$6.80
Footnotes
F5
CMMB holding Derivative

Stock option (right to buy American Depositary Shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
American Depositary Shares
Underlying amount
4,221
Exercise price
$3.44
Footnotes
F6
CMMB holding Derivative

Stock option (right to buy American Depositary Shares)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
18 Mar 2026
Ownership
Direct
Underlying class
American Depositary Shares
Underlying amount
6,599
Exercise price
$5.24
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The options reported in this row were granted to the Reporting Person by the Issuer on October 28, 2016, and are fully vested and exercisable as of the date of this report.

Footnote F2

The options reported in this row were granted to the Reporting Person by the Issuer on April 19, 2021, and are fully vested and exercisable as of the date of this report.

Footnote F3

The options reported in this row were granted to the Reporting Person by the Issuer on March 7, 2022, and are fully vested and exercisable as of the date of this report.

Footnote F4

The options reported in this row were granted to the Reporting Person by the Issuer on March 21, 2023, and are fully vested and exercisable as of the date of this report.

Footnote F5

The options reported in this row were granted to the Reporting Person by the Issuer on June 14, 2023, and vest and become exercisable in 36 equal monthly installments of 2.77%, such that all options reported in this row will be exercisable on June 14, 2026.

Footnote F6

The options reported in this row were granted to the Reporting Person by the Issuer on June 1, 2024, and are fully vested and exercisable as of the date of this report.

SEC remarks

This Form 3 has been filed after March 18, 2026 but prior to April 20, 2026 in reliance on the temporary relief made available to the directors and officers of certain foreign private issuers by the Staff of the Securities and Exchange Commission in its no-action letter dated March 13, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .